16 December 2025
Disclaimer: This is a simplified summary of a public company filing. See full disclaimer here.
Polomar Health Services, Inc.
CIK: 1265521•2 Annual Reports•Latest: 2025-05-22
10-K / May 22, 2025
Revenue:$58,824
Income:-$1,341,333
10-K / April 15, 2024
Revenue:$34,526
Income:-$416,500
10-K / May 22, 2025
Company Overview Summary
Core Business Operations
- Main Entity: Polomar Health Services Inc.
- Industry: Healthcare, pharmaceuticals, and compounding pharmacy services.
- Primary Operations:
- Operates Polomar Specialty Pharmacy, LLC, a licensed retail compounding pharmacy based in Palm Harbor, Florida.
- Engages in specialized pharmaceutical compounding of sterile and non-sterile medications, primarily injectable drugs, eye drops, infused therapeutics.
- Functions under federal guidelines for compounding pharmacies (Section 503A of the FD&C Act).
- Authorized to fulfill prescriptions in 28 U.S. states; actively seeking approval in additional states with plans to operate nationwide by the end of 2025.
- Planning to apply for a drug export permit in early 2025.
Digital Platforms and Future Products
- SlimRx: An online platform focused on weight loss medication management, connecting patients with licensed physicians.
- Prescriptions for weight loss drugs like semaglutide (compounded with vitamin B-12) and metformin are fulfilled by Polomar.
- Filed a trademark application on August 29, 2024.
- Current revenue primarily from pharmacy operations, no significant digital platform revenue reported yet.
- Upcoming Launches:
- PoloMeds: A platform launching in Q2 2025 for:
- Diabetes medications (metformin, insulin, sulfonylureas)
- Compounded erectile dysfunction treatments (inhalable sildenafil)
- Specialized dermatological formulations (treatments for acne, alopecia areata, basal cell carcinoma, vitiligo).
- Business model includes providing prescription fulfillment for third-party tele-health platforms (steady growth expected over 12-18 months).
- PoloMeds: A platform launching in Q2 2025 for:
Revenue and Financials
- Revenue (2024): $58,824
- Revenue (2023): $41,844
- Operating Expenses (2024): $1,330,399
- Net Loss (2024): $1,341,333
- Net Loss (2023): $587,997
- Current Cash (as of Dec 31, 2024): $6,191
- Total Assets (as of Dec 31, 2024): approximately $9.95 million (primarily from intangible intellectual property assets)
- Liabilities:
- Total current liabilities: $1,337,778
- Total long-term liabilities: $14,864
- Shareholders’ Equity:
- Negative $2,911,163 (due to net losses and accumulated deficits).
Employees and Management
- Number of Employees: 2 full-time, 2 part-time, and 1 consultant (Terrence M. Tierney, CEO).
- Management:
- CEO and President: Terrence M. Tierney
- CFO and Treasurer: Charlie Lin (appointed April 10, 2025)
- Former officers included Brett Rosen (resigned March 2024), with management recently shifted.
- Employees are based in the U.S. (California and Florida offices).
Business Strategy and Future Outlook
- The company has an early-stage business model with limited operating history and no material recurring revenue yet.
- Focused on building out its pharmacy license network, expanding product offerings, and developing digital health platforms.
- Plans to raise additional capital to fund operations, marketing, and product development.
- The company is a smaller reporting company, with minimal current revenue and significant net losses, and has ongoing plans to grow its pharmacy and digital services footprint nationwide.
